RXRX vs SNDX: Which Stock Is the Better Buy?
Recursion Pharmaceuticals, Inc. and Syndax Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — RXRX vs SNDX, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Recursion Pharmaceuticals, Inc. (RXRX) | Syndax Pharmaceuticals, Inc. (SNDX) | |
|---|---|---|
| Market cap | $1.6B | $1.6B |
| Revenue (latest FY) | $74.26M | $172.35M |
| Net income (latest FY) | $-644.76M | $-285.42M |
| Revenue growth (5y CAGR) | 79.7% | 157.7% |
| Net margin | -868.3% | -165.6% |
| Return on equity | -57.0% | -441.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full RXRX vs SNDX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open RXRX's full financials → Open SNDX's full financials →More comparisons
Frequently asked questions
Which is bigger, RXRX or SNDX?
Recursion Pharmaceuticals, Inc. is larger by market capitalization — $1.6B versus $1.6B.
Which grows faster, RXRX or SNDX?
Over the last five fiscal years, Syndax Pharmaceuticals, Inc. grew revenue faster — 157.7%/yr versus 79.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
RXRX fundamentals → · SNDX fundamentals → · All 1,500+ companies → · Free screener →